bioMerieux SA · EURONEXT:BIM
bioMerieux SA — FY2006 Earnings Presentation
41 slides from bioMerieux SA's earnings presentation, Mar 19, 2007
Slide 1: 2006 Results
2006 Results March 19, 2007 BIOMEIRIEUX
Slide 2: Disclaimer
Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial and competitive uncertainties in France or in other countries. Further i
Slide 3: Outline
Outline Sustained Growth Financial Results 2007 News and Objectives Questions and Answers 2
Slide 4: Outline
Outline Sustained Growth Z Operating Highlights Other Events Financial Results 2007 News and Objectives Questions and Answers 3
Slide 5: Sustained growth
Sustained growth ` Higher sales and earnings, in line with objectives Z Sales: €1,037m + 5.9% * Z Operating margin before non-recurring items: 14.4%, vs. 14% in 2005 Z Net income: €105m + 17% ` Refocusing on strategic businesses Z Divestment of the hemostasis line Z Discontinuation of microplate pro
Slide 6: Sales growth by region
Sales growth by region North America: 26% EMEA*: 56% + 6.9% + 5% (+ 8.3% excl. France) + 5.9% Latin America: 7% Asia Pacific: 11% + 7.1% + 7.9% *Europe, Middle East and Africa 5 Growth rates are like-for-like
Slide 7: Sales by technology
Sales by technology ` Clinical applications: €894m + 5.1% 49% Z Bacteriology: €506m + 6.5% Z Immunoassays*: €302m + 1.4% Z Molecular biology: €40m + 45.9% 29% 14% 4% ` Industrial applications: 4% €143m + 11.5% €47m Bacteriology Immunoassays Industry Molecular biology Other *Including the VIDAS / VID
Slide 8: Steady growth in the installed base
Steady growth in the installed base ` No change in the “instruments sold/instruments placed” mix Installed base: Sales by segment Number of new instruments installed* 3,900 3,900 4.7% 11.9% 3,600 3,500 83.4% Reagents Instruments Services 2003 2004 2005 2006 *Excluding hemostasis instruments and Dive
Slide 9: Outline
Outline Sustained Growth Operating Highlights Z Other Events Financial Results 2007 News and Objectives Questions and Answers 8
Slide 10: Refocusing on the strategic lines
Refocusing on the strategic lines ` Divestment of the hemostasis line Z Non-strategic, highly competitive segment Z Sales: › 2005: €45m › 2006: €28m Z €10m capital gain at December 31, 2006 ` Discontinuation of microplate production in North America Z Insufficient prospects for growth and profitabil
Slide 11: The microbiology laboratory
The microbiology laboratory BacT/ALERT® PPM / ChromIDTM VITEK®2 AESTM Blood sample Blood culture Identification and/or Interpretation Gram+ / Gram- Culture antibiogram of results Urine sample Slides DiversiLab® 10
Slide 12: DiversiLab
DiversiLab® Extraction and amplification of genetic material ` Fast fingerprinting: process completed in 4 hours vs. 10 to 72 hours ` Cost: half as much Real-time results analyzed by Detection expert software 11
Slide 13: Business development
Business development ` Acquisition of a 15% stake in ReLIA Z Enhanced presence in the point-of-care segment Z Rapid identification tests Z Platform distributed by bioMérieux in certain countries Z Cost: $8 million 12
Slide 14: Other highlights of the year
Other highlights of the year ` Exclusive agreement with Profos AG: Z Solutions to improve the preparation of food samples Z For faster, more selective, more reliable pathogens detection ` Agreement with Fudan University Cancer Hospital: Z Creation of a tumor marker research laboratory in Shanghai `
Slide 15: New products
New products Bacteriology Molecular biology Immunoassays ` Internal R&D: PPM Strepto B ID VIDAS TOROPonin I Ultra VITEK2 N, Haemophilus ID VIDIA Ferritine, TSH, VITEK2 VRSA AST FT3, FT4 EASYQ H5N1 ruo 25 reagents, including EASYQ HSV PPM CampyFood VIDAS LDUO Media β lactamase TEMPO Enterobacteria 6
Slide 16: Outline
Outline Sustained Growth Financial Results Z Income Statement Statement of Cash Flows and Balance Sheet 2007 News and Objectives Questions and Answers 15
Slide 17: Consolidated income statement
Consolidated income statement in € millions 2006 2005 % Change Net sales 1,037 994 + 4%* Operating income before non-recurring items 149 139 + 8% As a % of sales 14.4% 14.0% Operating income 152 139 + 10% As a % of sales 14.7% 14.0% Net income 105 90 + 17% As a % of sales 10.2% 9.1% *5.9% like-for-l
Slide 18: Analysis of growth in net sales
Analysis of growth in net sales €57.6m Change in scope of + 5.9% consolidation Currency €(13.9)m effect - 1.4% €1,036.9m €(0.3)m 0.0% Hemostasis (2nd half) Organic growth and BBI €993.6m + €43.3m + 4.4% 2005 2006 17
Slide 19: Analysis of growth in net sales
Analysis of growth in net sales Excluding hemostasis Change in €60m scope of consolidation + 6.3% Currency €(13.9)m Hemostasis effect - 1.4% (1st half) €1,036.9m €(0.3)m €(2.4)m 0.0% Hemostasis (2nd half) and BBI €993.6m Organic growth + 5.9% + €43.3m + 4.4% 2005 2006 18
Slide 20: Consolidated income statement
Consolidated income statement in € millions 2006 2005 % Change Sales 1,037 994 + 4%* Operating income before non-recurring items 149 139 + 8% As a % of sales 14.4% 14.0% Operating income 152 139 + 10% As a % of sales 14.7% 14.0% Net income 105 90 + 17% As a % of sales 10.2% 9.1% * + 5.9% like-for-li
Slide 21: Consolidated income statement
Consolidated income statement in € millions 2006 2005 % Change Sales 1,037 994 + 4%* Operating income before non-recurring items 149 139 + 8% As a % of sales 14.4% 14.0% Operating income 152 139 + 10% As a % of sales 14.7% 14.0% Net income 105 90 + 17% As a % of sales 10.2% 9.1% * + 5.9% like-for-li
Slide 22: Consolidated income statement
Consolidated income statement in € millions 2006 2005 % Change Sales 1,037 994 + 4%* Operating income before non-recurring items 149 139 + 8% As a % of sales 14.4% 14.0% Operating income 152 139 + 10% As a % of sales 14.7% 14.0% Net income 105 90 + 17% As a % of sales 10.2% 9.1% * + 5.9% like-for-li
Slide 23: Analysis of growth in operating income before non-recurring items
Analysis of growth in operating income before non-recurring items Gross profit SG&A Operating income before non-recurring €(13.5)m R&D / IP items Operating €21.5m €2.6m income before non-recurring items €149.4m €138.8m 14.4% of sales + €10.6m 14.0% of sales + 7.6% 2005 2006 22
Slide 24: Gross profit
Gross profit Organic growth QA/QC Other Gross profit €(5.8)m €4.4m €15.2m in 2006 ` Favorable €22.9m (€9.4m in 2005) currency effect ` Resolution of the HIV dispute Gross profit ` Stable raw materials prices + 4.4% of sales (52.4% in 2005) ` Transition €541.9m contract with Trinity Biotech 52.3% of
Slide 25: Selling, general and administrative expense
Selling, general and administrative expense Gross profit SG&A Operating income before non-recurring €(13.5)m R&D / IP items Operating €21.5m €2.6m income before non-recurring items 26.3% of sales €149.4m (26.1% in 2005) €138.8m ` Internal reorganization 14.4% of sales ` Divestment of 14.0% of sales
Slide 26: R&D costs stable
R&D costs stable Gross profit SG&A Operating income before non-recurring €(13.5)m R&D / IP items Operating €21.5m €2.6m income before non-recurring items 12.5% of sales €149.4m ` Higher R&D budgets €138.8m ` Business 14.4% of sales development costs down €5.5m 14.0% of sales ` Increased income from
Slide 27: Analysis of growth in net income
Analysis of growth in net income Net financial Income tax Associates Other Operating non-recurring expense €1.8m €(1.4)m Net income Income before income non-recurring €1.3m items €3.0m €10.6m Net income €105.4m €90.1m 10.2% of sales + €15.3m 9.1% of sales + 16.9% 2005 2006 26
Slide 28: Refocusing on strategic lines
Refocusing on strategic lines Net financial Income tax Associates Other Operating non-recurring expense €1.8m €(1.4)m Net income Income before income non-recurring €1.3m items €3.0m €10.6m Net income ` Net capital gain €105.4m on the hemostasis €90.1m divestment: 10.2% of sales €10.1m ` Charge for d
Slide 29: Improvement in net financial expense
Improvement in net financial expense Net financial Income tax Associates Other Operating non-recurring expense €1.8m €(1.4)m Net income Income before income non-recurring €1.3m items €3.0m €10.6m Net income ` Reduction in €105.4m average debt €90.1m 10.2% of sales 9.1% of sales 2005 2006 28
Slide 30: Tax rate: 30.4%
Tax rate: 30.4% Net financial Income tax Associates Other Operating non-recurring expense €1.8m €(1.4)m Net income Income before income non-recurring €1.3m items €3.0m €10.6m Net income ` Increase in R&D €105.4m tax credits (€5.5m vs. €3.3m in 2005) €90.1m ` Resolution of the 10.2% of sales HIV disp
Slide 31: Associates
Associates Net financial Income tax Associates Other Operating non-recurring expense €1.8m €(1.4)m Net income Income before income non-recurring €1.3m items €3.0m €10.6m ReLIA Net income €105.4m €90.1m 10.2% of sales 9.1% of sales 2005 2006 30
Slide 32: Earnings per share
Earnings per share Dividend recommended to shareholders + 17% €0.76 per share + 12% (or €30m €2.67 payout) + 30% €2.28 Payout ratio €2.04 raised to 30% €1.57 beginning with the dividend to be paid in 2008 2003* 2004 2005 2006 31 *Based on French GAAP net income before amortization of goodwill
Slide 33: Outline
Outline Sustained Growth Financial Results Income Statement Z Statement of Cash Flows and Balance Sheet 2007 News and Objectives Questions and Answers 32
Slide 34: Free cash flow: €57m
Free cash flow: €57m in € millions Dec. 31, 2006Dec. 31, 2005 Change EBITDA (1) 220 209 11 Provisions and other -14 5 -19 Cash flow before tax and financial expense 206 214 -8 Operating working capital requirement -29 1 -30 income tax and financial expense -55 -48 -7 Capital expenditure (2) -89 -82
Slide 35: Sustained capital expenditure
Sustained capital expenditure 2006 2005 €47m €38m Instruments €41m €45m Other capex Total €88m 8.5% of sales €83m 8.4% of sales Change in payables to equipment suppliers 1m - 1m Cash outlays €89m €82m 34
Slide 36: A solid balance sheet
A solid balance sheet Assets Liabilities Goodwill €75m Instruments €66m Other non-current €558m Equity assets €303m WCR €124m €10m Net debt Operating WCR: 22% of sales 35
Slide 37: Outline
Outline Sustained Growth Financial Results 2007 News and Objectives Questions and Answers 36
Slide 38: Executing the strategy
Executing the strategy ` Focusing on pathologies and clinicians’ needs 2007 News Bacteriology Molecular biology Immunoassays Z Infectious agents Biomedics* Z Clinical applications • Sepsis GeneXpert ChromID VRE • Hospital-acquired infections ChromID ESBL DiversiLab (USA) • Tuberculosis • HIV/hepatit
Slide 39: Strengthened operations
Strengthened operations ` Geographic focus: Z Japan: VITEK®2 XL order from BML Z United States: launch of TEMPO® ` Time to market: Z Introduction of a cross-functional team ` Information technologies: Z Appointment of Mojgan Lefebvre 38
Slide 40: 2007 objectives
2007 objectives ` Sales Z Sustained deployment of the new platforms and enriched reagent menus Z Refocusing on the strategic lines 6 to 7% growth in net sales* ` Operating margin before non-recurring items Z 2012 objective: gradual 100 to 150 bp improvement on 2006 (at constant exchange rates) Z Gro
Slide 41: Outline
Outline Sustained Growth Financial Results 2007 News and Objectives Questions and Answers 40